| 王一鸣,焦 旸.局部进展期直肠癌新辅助放疗联合免疫治疗的现状与挑战[J].肿瘤学杂志,2025,31(8):657-663. |
| 局部进展期直肠癌新辅助放疗联合免疫治疗的现状与挑战 |
| Current Status and Challenges of Neoadjuvant Radiotherapy Combined with Immunotherapy for Locally Advanced Rectal Cancer |
| 投稿时间：2024-12-03 |
| DOI：10.11735/j.issn.1671-170X.2025.08.B002 |
|
 |
| 中文关键词: 直肠肿瘤 局部进展期 新辅助放疗 免疫治疗 |
| 英文关键词:rectal neoplasms locally advanced neoadjuvant radiotherapy immunotherapy |
| 基金项目: |
|
| 摘要点击次数: 253 |
| 全文下载次数: 104 |
| 中文摘要: |
| 摘 要：近年来，新辅助放疗联合免疫治疗在局部进展期直肠癌（locally advanced rectal cancer，LARC）治疗中体现出潜在的应用价值，针对新辅助放疗联合免疫治疗方案相关的临床研究均取得了一定的进展。此外，许多针对微卫星稳定型LARC的开创性联合治疗研究也在不断探索中，如添加细胞因子、靶向肿瘤乏氧、调节肠道菌群等。但新辅助放疗联合免疫治疗仍面临疗效评估指标不完善、毒性与安全性不明确及缺乏标准化方案等问题。全文总结LARC在新辅助放疗联合免疫治疗研究中的发展现状及其面临的问题，为优化LARC联合治疗方案的相关基础与临床研究提供理论依据。 |
| 英文摘要: |
| Abstract： In recent years， neoadjuvant radiotherapy combined with immunotherapy has demonstrated potential value in the treatment of locally advanced rectal cancer (LARC). Clinical studies investigating these combined regimens have achieved significant progress. Furthermore， pioneering research on combination therapies for microsatellite-stable LARC is under active investigation， including strategies such as cytokine supplementation， tumor hypoxia targeting， and intestinal microbiota modulation. However， neoadjuvant radiotherapy combined with immunotherapy still faces challenges， including suboptimal efficacy assessment indices， insufficient clarity on toxicity and safety profiles， and the absence of standardized protocols. This paper summarizes the current developments and challenges in neoadjuvant radiotherapy combined with immunotherapy for LARC， providing new insights for future basic and clinical research on LARC combination therapies. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |